Tags: Drug.
Cabozantinib (marketed under the tradename Cometriq formerly known as XL184) is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2 and has been shown to reduce tumor growth metastasis and angiogenesis.It was developed by Exelixis Inc. Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011.Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer.
